Zami Aberman
2012
In 2012, Zami Aberman earned a total compensation of $1.5M as Chief Executive Officer at Pluristem Therapeutics, a 14% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $75,000 |
|---|---|
| Salary | $495,623 |
| Stock Awards | $899,500 |
| Other | $21,771 |
| Total | $1,491,894 |
Aberman received $899.5K in stock awards, accounting for 60% of the total pay in 2012.
Aberman also received $75K in non-equity incentive plan, $495.6K in salary and $21.8K in other compensation.
Rankings
In 2012, Zami Aberman's compensation ranked 4,588th out of 11,487 executives tracked by ExecPay. In other words, Aberman earned more than 60.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,588 out of 11,487 | 60th |
Division Manufacturing | 1,594 out of 4,253 | 63rd |
Major group Chemicals And Allied Products | 366 out of 1,198 | 69th |
Industry group Drugs | 228 out of 920 | 75th |
Industry Biological Products, Except Diagnostic Substances | 40 out of 160 | 75th |
Source: SEC filing on March 29, 2013.
Aberman's colleagues
We found one more compensation record of an executive who worked with Zami Aberman at Pluristem Therapeutics in 2012.
2012
Yaky Yanay
Pluristem Therapeutics
Chief Financial Officer
News
Pluristem Therapeutics CEO Yaky Yanay's 2022 pay falls 86% to $1.3M
February 27, 2023
Pluristem Therapeutics Chairman Zami Aberman's 2020 pay falls 54% to $501K
April 8, 2021
Pluristem Therapeutics Chairman Zami Aberman's 2019 pay jumps 85% to $1.1M
May 20, 2020
Pluristem Therapeutics CEO Zami Aberman's 2018 pay falls 83% to $593K
April 25, 2019